Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder
Status:
Unknown status
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
Patients with major depressive disorder (MDD) commonly have many gastrointestinal complaints.
Gastrointestinal pain is classified into 2 categories: visceral and somatic pain. The main
aim of this study is to compare somatic and visceral sensitivity between healthy people and
pateints with MDD. These two sensitivities will be assessed by the 2 following tests:
standardized rectal distension and Transdermal transcutaneous electric nerve stimulation.
Thereafter, patients with MDD will be randomly allocated to escitalopram or reboxetine. After
6 weeks of treatment, somatic and visceral sensitivity will be reassessed.
Phase:
Phase 4
Details
Lead Sponsor:
Hospital Universitari Vall d'Hebron Research Institute